Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了一个第二收入来源,该来源源于现有运营、资产、客户或能力,并且已经产生实际付费业务,同时管理层正在刻意投入资源发展它。 在记录中,管理层讨论了Stelo产品,这是为不使用胰岛素的2型糖尿病患者设计的CGM。Kevin Sayer说:“我们很高兴推出我们的最新产品Stelo,今年夏天晚些时候。Stelo将是第一款专门为不使用胰岛素的2型糖尿病患者设计的CGM。利用我们领先的传感器平台,我们构建了一个定制软件体验,以满足这一人群的需求。Stelo将具有15天的佩戴时间,并将作为现金支付产品推出,同时我们建立与支付方的案例以获得更广泛的覆盖。” 这似乎是一个新产品,针对不同的患者群体(非胰岛素使用者),但它是基于现有传感器平台构建的。它是否构成一个“第二收入来源”?它仍然是CGM销售,但针对不同的细分市场。然而,管理层将其视为一个独立的增长机会,并计划投资于它。Jereme Sylvain说:“从运营利润率来看,是的,这是我们正在投资的事情。因此,当你从整体公司利润率的角度考虑时,当然,随着我们投资于此并推出它,会有一些销售和营销,但这是我们今年要做的投资。我们将进行这项投资,因为我们对未来有信心,并且我们将在扩大公司盈利能力的同时这样做。” 但这是否是“源于现有运营的第二收入来源”?它确实源于现有技术平台,但它是同一产品线的延伸,针对不同的客户群。它是否被视为“不同的收入流”?管理层将其视为一个单独的产品,具有不同的定价和分销模式。然而,它仍然是CGM销售,只是针对不同的患者群体。它是否构成“第二收入来源”?可能不是,因为它仍然是同一核心业务(CGM)的销售,只是针对不同的细分市场。它更像是产品线扩展,而不是一个不同的收入流。 此外,管理层还讨论了Dexcom ONE,这是国际市场上的一个产品,但这也是CGM销售。 另一个可能的候选是“直接面向手表”功能,但这只是功能,不是收入流。 管理层没有提到任何其他收入来源,如许可、数据货币化等。 因此,我认为没有描述一个“第二收入来源”。Stelo是同一核心业务的产品线扩展,而不是一个不同的收入流。它仍然是销售CGM传感器,只是针对不同的患者群体。它没有产生不同的收入类型。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.